Remarkably, we found that simultaneous treatment of NRAS-mutant cells with the MEK inhibitor trametinib and either hydroxyurea or aphidicolin resulted in significantly stronger melanoma growth inhibition in cell culture (Figure 9C) and in mice (Figure 9D) than either drug alone. The gene discussed is MAP2K7; the disease is melanoma.